RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Cash and cash equivalents

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 2024969+18.87%
Dec 31, 2023815-5.95%
Dec 31, 2022866+5.66%
Dec 31, 2021820+65.12%
Dec 31, 2020497-9.25%
Dec 31, 2019547+30.24%
Dec 31, 2018420-34.90%
Dec 31, 2017645+233.32%
Dec 31, 2016194+7.03%
Dec 31, 2015181+140.62%
Dec 31, 201475+41.40%
Dec 31, 201353+3.43%
Dec 31, 201251-26.80%
Dec 31, 201170-5.86%
Dec 31, 201075

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)